Digestive Health Research of North Texas
Digestive Health Research of North Texas
Wichita Falls, Texas, United States6 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Crystal Arthropathies, Nutritional and Metabolic Diseases, arthritic joint disease, arthropathy, gout, hereditary disease, inborn disorder of purine or pyrimidine metabolism, inborn errors of metabolism, metabolic disease, musculoskeletal system disorder, rheumatic disorder | Recruiting | Phase 2 | 2026-09-28 | NCT07535034 | |
| A Study of Dotinurad Versus Allopurinol in Tophaceous Gout | Hyperuricemia, Pathologic Processes, Pathological Conditions, Signs and Symptoms | Recruiting | Phase 3 | 2026-09-28 | NCT07089888 | |
| A Study of Dotinurad Versus Allopurinol in Participants With Gout | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Crystal Arthropathies, Hyperuricemia, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arthritic joint disease, arthropathy, gout, hereditary disease, inborn disorder of purine or pyrimidine metabolism, inborn errors of metabolism, metabolic disease, musculoskeletal system disorder, rheumatic disorder | Recruiting | Phase 3 | 2026-09-28 | NCT07089875 | |
| Study of DONQ52 in Active Celiac Disease | Digestive System Diseases, Nutritional and Metabolic Diseases, celiac disease, digestive system disorder, intestinal disorder, malabsorption syndrome, metabolic disease | Recruiting | Phase 2 | 2026-08-14 | NCT07239336 | |
| A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Active, not recruiting | Phase 3 | 2026-07-02 | NCT04849728 | |
| Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Active, not recruiting | Not stated | 2026-05-14 | NCT04136002 |